Abcuro

“Abcuro, rare disease biotech, raised $66 million Series D for monoclonal antibody treatments for inclusion body myositis, a rare autoimmune muscle disease”

“Abcuro, a Massachusetts-based developer of immunotherapies for autoimmune diseases, raised a $66 million Series D led by New Leaf Venture Partners.”